Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling $245M

Published on :

Ascentage Pharma (6855.HK), a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics (1801.HK, “Innovent”), today announced a multifaceted strategic collaboration.